

K250995 Xpert Xpress CoV-2/Flu/RSV plusMay 1, 2025
30 days to decisionK250995 · Product code: **QOF** · Microbiology
Source: <https://www.510kdatabase.net/k250995/>**SUBMISSION DETAILS**

| | |
|-----------------------|---|
| Decision | Substantially Equivalent (Cleared) |
| Submission type | Special |
| Device classification | Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents (QOF) |
| Date received | Apr 1, 2025 |
| Decision date | May 1, 2025 |
| Days to decision | 30 days |
| Third-party review | No |
| Combination product | No |
| PCCP authorized | No |
| Summary / Statement | Summary |

APPLICANT

| | |
|----------------|---|
| Company | Cepheid |
| Location | Sunnyvale, CA, US |
| Contact | Suzette Chance |
| Website | https://www.cepheid.com |
| 510(k) history | 60 submissions · 57 cleared · 2006-2026 |

Cepheid is a molecular diagnostics company based in Sunnyvale, US. The company enables access to molecular diagnostic testing globally through its Xpert platform and related solutions. Cepheid has received FDA 510(k) clearances from total submissions since its first clearance in 2006. The company specializes in Microbiology devices, which represent 93% of its regulatory submissions. Its latest FDA 510(k) clearance in 2026 demonstrates continued active development and market presence. Recent cleared devices span respiratory diagnostics, infectious disease detection, antimi...

510k Database - www.510kdatabase.netDevice record: <https://www.510kdatabase.net/k250995/> Data sourced from FDA 510(k) public records (accessdata.fda.gov).510k Database is an independent platform not affiliated with the U.S. Food and Drug Administration. Always verify at accessdata.fda.gov. - Generated May 13, 2026